nsc 262266 profile

NSC 262266: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	6438713
MeSH ID	M0197228

Synonym
73387-70-9
nsc 262666
1,4-diazoniabicyclo(2.2.1)heptane, 1,4-bis(2-chloroethyl)-,(z)-2-butenedioate (1:2)
1,4-diazoniabicyclo(2.2.1)heptane, 1,4-bis(2-chloroethyl)-, (z)-2-butenedioate (1:2)
1,4-bis(2-chloroethyl)-1,4-diazoniabicyclo(2.2.1)heptane (z)-2-butenedioate (1:2)
nsc 262664
nsc 262266
2-butenedioic acid, (z)-, ion(1-), 1,4-bis(2-chloroethyl)-1,4-diazoniabicyclo(2.2.1)heptane (2:1)
1,4-bis(2-chloroethyl)-1,4-diazoniabicyclo[2.2.1]heptane;(z)-4-hydroxy-4-oxobut-2-enoate

Research Excerpts

Excerpt	Reference	Relevance
"Cardiotoxicity, a side-effect that can occur after treatment with an anticancer drug, has severe clinical implications."	( In vitro screening of antitumour agents for cardiotoxicity by means of isolated mouse left atria. Bast, A; Haenen, GR; van Acker, FA; van Acker, SA; van der Vijgh, WJ, )	0.13

Excerpt	Relevance	Reference
"We investigated the antitumoral activity of Dabis Maleate given on different dosage schedules and as continuous infusion in a murine reticular cell sarcoma M5076 (M5) and in a subline made resistant to cyclophosphamide and other nitrogen mustards (M5/CTX)."	( Antitumor activity of 1,4-bis (2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis Maleate) in M5076 and its subline resistant to cyclophosphamide M5/CTX. D'Incalci, M; Filippeschi, S; Hendricks, H; Tagliabue, G, 1992)	0.28

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	4 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (20.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	4 (80.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
cb 10375 trimelamol: structure given in first source	1.98	1
carmethizole carmethizole: RN & structure given in first source; RN given refers to HCl; RN for parent cpd not available 2/89	1.98	1
pancratistatin pancratistatin: an isocarbostyril from Amaryllidaceae	1.98	1	citraconoyl group
rhizoxin rhizoxin: from Rhizopus chinensis; causal agent of rice seedling blight; structure given in first source. rhizoxin : An macrolide antibiotic isolated from the pathogenic plant fungus Rhizopus microsporus. It also exhibits antitumour and antimitotic activity.	1.98	1	1,3-oxazoles; epoxide; macrolide antibiotic	antimitotic; antineoplastic agent; metabolite
bryostatin 1 bryostatin 1: a protein kinase C activator; macrocyclic lactone from marine Bryozoan Bugula neritina; RN given refers to (1S-(1R,3R,5Z,7S,8E,11R,12R(2E,4E),13E,15R,17S(S),21S,23S,25R))-isomer; structure given in first source; activates protein kinase c. bryostatin 1 : A member of the class of bryostatins that is (17E)-2-oxooxacyclohexacos-17-ene which is substituted by hydroxy groups at positions 4, 10, and 20; an acetoxy group at position 8; methyl groups at positions 9, 9, 18, and 19; 2-methoxy-2-oxoethylidene groups at positions 14 and 24; an (E,E)-octa-2,4-dienoyloxy group at position 21; and with oxygen bridges linking positions 6 to 10, 12 to 16, and 20 to 24. It is one of the most abundant member of the class of bryostatins.	1.98	1

Condition	Relationship Strength	Studies	Trials
Diffuse Large B-Cell Lymphoma [description not available]	1.98	1	0
Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.	1.98	1	0
Benign Neoplasms [description not available]	3.36	1	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.36	1	1
Adenocarcinoma, Basal Cell [description not available]	1.97	1	0
Adiadochokinesis [description not available]	1.97	1	0
Dysesthesia [description not available]	1.97	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	1.97	1	0
Cerebellar Ataxia Incoordination of voluntary movements that occur as a manifestation of CEREBELLAR DISEASES. Characteristic features include a tendency for limb movements to overshoot or undershoot a target (dysmetria), a tremor that occurs during attempted movements (intention TREMOR), impaired force and rhythm of diadochokinesis (rapidly alternating movements), and GAIT ATAXIA. (From Adams et al., Principles of Neurology, 6th ed, p90)	1.97	1	0